12:00 AM
 | 
Oct 08, 2007
 |  BioCentury  |  Product Development

PASI 75 comparisons

PASI 75 comparisons

PASI 75 comparisons
Based on Phase III data announced last week for plaque psoriasis, Johnson & Johnson's ustekinumab (CNTO 1275) looks to be as good as the two best biologics - Humira and Remicade - in terms of efficacy and better in terms of dosing. JNJ's antibody targeting interleukin-12 (IL-12) and IL-23 met the trial's primary endpoint as 67% and 76% of patients in the 45 and 90 mg dose groups acheived a PASI 75 score at week 12, respectively, compared with 4% of placebo patients (p<0.001 for both). In addition, 42% and 51% of patients in the low- and high-dose ustekinumab groups had a PASI 90 compared with...

Read the full 561 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >